UNSPSC 51281647: Framycetin sulfate

This classification denotes an aminoglycoside antibiotic with the molecular formula C23H46N6O13.3H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y3720KZ4TQ, chemically known as neomycin b, sulfate (salt) but more generally known as framycetin sulfate, which bears US NIH Compound Identifier 197162. European Medicines Agency schedules Framycetin sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02269MIG.

UNSPSC 51281647 Framycetin sulfate is a Commodity code, but the recent state and local contract opportunities tagged under it reflect no procurement activity for framycetin sulfate itself. Instead, the code has captured unrelated solicitations for naloxone and drug deactivation systems, direct-to-manufacturer pharmacy programs, medical and first aid supplies for emergency response, and generic multi-source pharmaceuticals and OTC products through cooperative purchasing. The mismatch between the code's nominal scope and actual buying activity suggests the code sees little relevant procurement velocity or that tagging practices at issuing bodies do not consistently align with the product nomenclature.

The geographic and issuing-body spread across recent opportunities spans Seminole County (Florida), the Texas Health and Human Services Commission, the City of Tampa, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), which serves multiple states including Oregon. Seminole County issued an IFB for naloxone and drug deactivation systems (due July 26, 2023) through community health initiatives; the City of Tampa issued an IFB for medical and first aid supplies for the Fire Department Rescue Division with an estimated contract value of $700,000 (due March 13, 2026); MMCAP issued an RFP for generic pharmaceuticals and OTC products with a March 26, 2026 deadline; and the Texas HHS Commission issued an RFI (due April 3, 2026) to gather vendor capabilities for direct-to-manufacturer prescription programs. The absence of framycetin-specific procurement signals and the presence of mis-tagged generalist pharmaceutical and emergency-supply solicitations indicate this code does not currently represent an active pursuit area for framycetin-based products in state and local markets.